

Curriculum Vitae
Kara C. Long, MD, MSc
1275 York Avenue
Howard 1308
New York, New York 10065
(w) 212.639.7043 (c) 919.423.5553
longrock@mskcc.org

Education

| | |
|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|
| August 1996 – May 2000 | University of Virginia Bachelor of Arts, Biology Charlottesville, Virginia |
| August 2001 – May 2005 | University of North Carolina School of Medicine Doctor of Medicine Chapel Hill, North Carolina |
| July 2011 – May 2013 | Weill Cornell Graduate School of Medical Sciences Master of Science, Clinical Epidemiology and Health Services Research New York, New York |

Post-graduate training

| | |
|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|
| July 2005 – June 2009 | Residency in Obstetrics and Gynecology New York University Medical Center Department of Obstetrics and Gynecology New York, New York |
| October 2007 | Galloway Resident Program Memorial Sloan-Kettering Cancer Center Department of Surgery, Gynecology Service New York, New York |
| July 2009 – June 2013 | Fellowship in Gynecologic Oncology Memorial Sloan-Kettering Cancer Center Department of Surgery, Gynecology Service New York, New York |

Academic Appointments & Employment

| | |
|-----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| September 2013 – April 2015 | Assistant Professor, Kelly Gynecologic Oncology Service Fellowship Education Coordinator Department of Gynecology and Obstetrics Johns Hopkins School of Medicine Baltimore, Maryland |
|-----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| | |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| May 2015 – Dec 2021 | Assistant Attending, Gynecology Service Section of Ovarian Cancer Surgery Department of Surgery Memorial Sloan Kettering Cancer Center New York, New York Assistant Professor, Obstetrics and Gynecology Weill Cornell Medical College, Cornell University New York, New York |
| Dec 2021 – present | Associate Attending, Gynecology Service Section of Ovarian Cancer Surgery Department of Surgery Memorial Sloan Kettering Cancer Center New York, New York |
| 2018 – present | Associate Director, Gynecologic Oncology Fellowship Program Department of Surgery Memorial Sloan Kettering Cancer Center New York, New York |
| 2024 - present | Site Director, Department of Surgery Basking Ridge, New Jersey MSK Regional Site |

Board Certification & Licensure

| | |
|-------------------------|---------------------------------------------------|
| November 2014 - present | Obstetrics and Gynecology, Board-certified |
| April 2017 - present | Gynecologic Oncology, Board-certified |
| June 2013 – 2015 | State of Maryland Medical License, #D76309 |
| January 2008 – present | State of New York Medical License, #247257 |
| November 2015 – present | State of New Jersey Medical License #25MA09796500 |

Honors/Awards

| | |
|-------------|--------------------------------------------------------------------------------------------------------------------------|
| 2004 – 2005 | Honors, University of North Carolina School of Medicine |
| 2005 | Eugene S. Mayer Honor Society University of North Carolina School of Medicine |
| 2009 | Achievement in Laparoscopic Surgery Award Department of Obstetrics & Gynecology New York University Medical Center |

| | |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2009 | Chief Resident Excellence in Teaching Award Department of Obstetrics & Gynecology New York University Medical Center |
| 2013 | The Michael E. Burt MD, PhD Memorial Award Department of Surgery, Memorial Sloan-Kettering Cancer Center <i>Given on an annual basis to a graduating fellow in recognition of superior clinical and operative skills and commitment to education</i> |
| 2014 | Excellence in Teaching and Mentorship Department of Gynecology & Obstetrics Johns Hopkins School of Medicine <i>Given by the graduating resident class of 2014</i> |
| 2020 | Excellence in Teaching Award Gynecology Service, Department of Surgery Memorial Sloan Kettering Cancer Center <i>Presented by the graduating fellowship class of 2020</i> |
| 2023 | David M. Livingston Collaboration Award Break Through Cancer <i>Presented at the 2023 BTC Summit for work done on Intercepting Ovarian Cancer</i> |

Memberships and Committees

| | |
|----------------|------------------------------------------------------------------------------------------------|
| 2005 - present | American Congress of Obstetricians and Gynecologists |
| 2009 – present | Society of Gynecologic Oncology |
| 2011 – 2012: | 2012 Annual Meeting on Women’s Cancer. <i>Co-chair: Resident, Fellow, Candidate Session</i> |
| 2018 – 2020: | Clinical Practice Committee, <i>member.</i> |
| 2019 – 2020: | 2020 Annual Meeting on Women’s Cancer. Steering Committee, <i>member.</i> |
| 2013 – present | American Society of Clinical Oncologists |
| 2015 – present | International Gynecologic Cancer Society |
| 2015 – 2016 | MSK Gynecology Service Treatment Planning Conference <i>Director</i> |
| 2016 – 2018 | MSK State of the Art Ovarian Cancer Conference <i>Course Co-Director</i> |
| 2017 - present | Society of Memorial Gynecologic Oncologists <i>Treasurer</i> |

| | |
|----------------|---------------------------------------------------------------------------------------------------------------------------|
| 2017 - present | MSK Surgery Protocol Review Committee 2021: <i>Vice Chair</i> 2023: <i>Chair</i> |
| 2018 | Gynecologic Oncology Fellows' Advanced Course in Cytoreductive Surgery for Ovarian Cancer <i>Course Co-Director</i> |
| 2018 – present | NRG Surgical Oncology Committee |
| 2020 – present | Any Mountain Expedition Team (<i>Anymountainsong.com</i>) <i>Research Team Member</i> |
| 2022 – present | International Gynecologic Oncology Society International <i>Fellowship Mentor/Site Liaison: Nigeria Ibadan</i> |
| 2025 – present | Outsmart Ovarian Cancer Collaborative |

Current Research

#23-020: A Multi-disciplinary Approach to Opportunistic Salpingectomy for the Primary Prevention of Ovarian Cancer (Active) Role: PI

#22-049: Perioperative Stress Reduction in Ovarian Cancer (PRESERVE Trial) - A Prospective Randomized Pilot Study (Active) Role: PI

#23-013: Risk-Reducing Salpingectomy with Delayed Oophorectomy as an Alternative to Risk-Reducing Salpingo-oophorectomy in High Risk Women to Assess the Safety of Prevention (TUBA-WISP II) – US Cohort Study, (Active) Role: MSK PI

#21-029: A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCK] (NRG-CC008) (CIRB). (Active) Role: MSK PI

#20-164: Advanced Ovarian Cancer: Treatment Patterns and Outcomes in High Volume Centers. (Active) Role: MSK PI

#16-604: Tina Brozman Ovarian Cancer Consortium (TBOCC). (Active) Role: MSK PI

#15-281: Uterine Washing Biomarkers as a Novel Screening Tool for High Grade Serous Carcinoma. (Closed for accrual) Role: MSK PI

#16-1617: Stand Up to Cancer: The WISP Trial (Women Choosing Surgical Prevention). (Closed for accrual) Role: MSK Co-PI

#21-025: Advanced Ovarian Cancer: Patterns of Response to NACT at the Time of IDS. (Closed for accrual) Role: MSK PI

#17-430: Evaluation of Patients Presenting with an Adnexal Complaint: Diagnostics, Management and Clinical Outcomes. (Closed for accrual) Role: MSK PI

#16-1378: Factors Associated with the Utilization of a High-Volume Cancer Center by Black Women with Ovarian Cancer: A Qualitative Study. (Closed for accrual) Role: MSK PI

Research Funding

Break Through Cancer
Opportunistic Salpingectomy to Reduce Ovarian Cancer
\$5,000,000

MSK Sub-Aim 3 PI: Kara Long Roche
3 year, multi-institutional grant

This project will set the foundation of scientific evidence to incorporate opportunistic salpingectomy into routine practice, and we be the basis for a public health campaign.

Any Mountain Expedition Team Grant
Exploring Decision Making in Risk-Reducing Gyn Surgery: A WISP Sub Study
\$30,000

PI: Kara Long Roche

A qualitative project exploring decision making in patients at high risk for ovarian cancer facing risk-reducing surgery.

Department of Defense
Implantable Nanosensor for Early-Stage Ovarian Cancer Detection (OC210292)
\$450,000

9/30/2022-9/29/2025

PI: Kara Long Roche, Dan Heller

This project develops an implantable sensor technology for the early detection of ovarian cancer.

Honorable Tina Brozman Foundation
Monitoring Intrauterine Biomarkers to Detect Pre-Invasive Disease
\$272,728

1/21/2022-1/20/2024

PI: Kara Long Roche, Dan Heller

This project utilizes the novel technique of uterine lavage for the early detection of ovarian cancer.

HTBF \$90,908.00,
Circulating and shed biomarkers for early detection of ovarian cancer
1/1/2017 - 12/31/2019

PI: Long Roche, Kara

To identify novel strategies for the early detection of ovarian cancer.

Invited Presentations

Institutional:

4/28/2016 Risk Reducing Surgical Options for Women at Genetic Risk of Gynecologic Cancer. Genetics and Genomics Conference.

- 11/17/2016 Identification and Evaluation of the High-Risk Patient.
State of the Art Ovarian Cancer Conference.
- 12/14/2017 Role of Hysterectomy in Risk-Reducing Surgery for Ovarian Cancer: Debate.
State of the Art Ovarian Cancer Conference.
- 10/04/2018 Perioperative Epidurals: Pain, Stress, and the Immune Response.
State of the Art Gynecologic Surgery and Ovarian Cancer Conference
- 1/24/2019 Finding the Balance for the High-Risk Patient: Risk-Reducing Options and the Estrogen
Dilemma. State of the Art Gynecologic Surgery and Ovarian Cancer Conference.
- 11/9/2021 Updates in Risk-Reducing Measures for Ovarian Cancer
BRCA 2021: Patient Symposium
- 1/29/2026 Gynecologic Risk-Reducing Surgery
BRCA Symposium 2026

National:

- 11/1/2013 Grand Rounds: Hereditary Breast and Ovarian Cancer: BRCA and Beyond.
Department of Obstetrics and Gynecology. Greater Baltimore Medical Center.
Baltimore, Maryland
- 5/18/2018 Grand Rounds: Hereditary Ovarian Cancer and Risk Reducing Surgery.
Department of Obstetrics and Gynecology, Maimonides Medical Center.
Brooklyn, NY
- 2/6/2018 Debulking Surgery for Advanced Gynecologic Cancers.
Foundation for Women's Cancer: Gynecologic Cancer Course.
Anchorage, Alaska
- 4/13/2018 Grand Rounds: Hereditary Ovarian Cancer and Risk Reducing Surgery.
Marshall University Health, Department of Obstetrics and Gynecology.
Huntington, WV
- 3/18/2019 Risk Reducing Surgery: Management Options and Controversies
Society of Gynecologic Oncology: Annual Meeting on Women's Cancer
Honolulu, HI
- 9/12/2019 Grand Rounds: Hereditary Ovarian Cancer: Risk reduction Strategies and Controversies
in Management. Hartford Hospital Department of Obstetrics and Gynecology.
Hartford, CT
- 1/15/2020 President's Guest Speaker: Updates in Ovarian Cancer
Miami Obstetrics and Gynecology Society. Miami, Florida
- 4/7/2021 Grand Rounds: Hereditary Ovarian Cancer: Strategies and Controversies
Department of Obstetrics and Gynecology. Staten Island University Hospital.
Staten Island, New York.
- 2022 Diaphragm Resection and Thoracic Lymphadenectomy.
Annual Meeting on Women's Cancer, Society of Gynecologic Oncology
Phoenix, AZ
- 2024 Minimally Invasive Interval Debulking Surgery for Advanced Ovarian Cancer: Debate

Annual Meeting on Women's Cancer, Society of Gynecologic Oncology
San Diego, CA

- 3/14/2025 The UN of OS: Opportunistic Salpingectomy. Annual Meeting on Women's Cancer, Society of Gynecologic Oncology. Seattle, WA.
- 10/7/2025 Radical Collaboration Across the House of Surgery to Eliminate Ovarian Cancer. American College Surgeons Annual Meeting. Chicago, IL.
- 1/21/2025 Moonshot in the OR: Opportunistic Salpingectomy for Primary Prevention of Ovarian Cancer. Grand Rounds at the Cleveland Clinic, Departments of Surgery, Obstetrics and Gynecology, and Urology.
- 1/30/2026 Green Means Go: Optimizing Bowel Anastomoses. Winter Society Gynecologic Oncology Meeting. Olympic Valley, CA.

International:

- 9/22/2018 Risk Reducing Surgery in Gynecologic Oncology: The Memorial Sloan Kettering Perspective. Wild West Symposium. Kliniken Essen-Mitte. Essen, Germany.
- 11/08/2019 D.A Boyes Society Keynote Speaker: Hereditary Ovarian Cancer and Risk Reducing Strategies. University of British Columbia. Vancouver, B.C.
- 12/05/2019 Advanced Course for Cytoreductive Surgery: Speaker and Anatomy Lab Proctor. Oslo University Hospital. Oslo, Norway.
- 12/06/2019 10th Trope Meeting: Hereditary Ovarian Cancer: BRCA and Beyond. Norwegian Radium Hospital. Oslo, Norway.
- 5/08/2020 Management of the Newly Diagnosed Patient with Ovarian Cancer: Who do we take for Primary Debulking Surgery? International Gynecologic Cancer Society Annual Film Festival.
- 10/8/2021 Radical resection of a retroperitoneal Mullerian adenocarcinoma with vascular bypass. International Gynecologic Cancer Society Surgical Film Festival, Ultra-Radical Procedures. International Gynecologic Cancer Society Annual Film Festival.
- 8/12/2023 Update on the Role of Surgery in the Management of Advanced Ovarian Cancer 8th APOLLO Symposium, Fudan University, Zhongshan Hospital

Community Outreach:

- 10/29/2014 Breast and Ovarian Cancer: High Risk Families and Management. Strategies Survivorship Course, Foundation for Women's Cancer. Baltimore, Maryland
- 9/4/2016 Ovarian Cancer in 2016: Advances in Screening, Prevention, and Reasons for Hope. Gynecologic Cancer Awareness Month Lecture Series, MSK.
- 9/13/2016 Ovarian Cancer in 2016: Advances in Screening, Prevention, and Reasons for Hope. Tina's Wish Lunch and Learn.
- 3/01/2016 Advances in Screening, Prevention, and Reasons for Hope. Tina's Wish Lunch and Learn.

| | |
|------------|----------------------------------------------------------------------------------------------------------------------------------|
| 6/15/2007 | Advances in Screening, Prevention, and Reasons for Hope. Tina's Wish Leadership Council Reception. |
| 2/04/2018 | Debulking Surgery for Ovarian Cancer. Foundation for Women's Cancer, Survivorship Course. Anchorage, AK. |
| 3/28/2018 | Advances in Screening, Prevention, and Reasons for Hope. Tina's Wish Women's Committee Luncheon. |
| 4/27/2018 | Ovarian Cancer: An Update on Treatment and Prevention in 2018. Cancer and Women of Color: A clinical and practical guide. SHARE. |
| 5/01/2018 | Hereditary Ovarian Cancer in 2018: Updates in Prevention. MSKCC Brooklyn Health Education Donor Seminar. |
| 6/04/2018 | Ovarian Cancer in 2018. Tina's Wish Leadership Council Spring Reception. |
| 1/14/2019 | Ovarian Cancer: Reasons for Hope in 2019. C200 & Tina's Wish: Cocktails for a Cause. |
| 10/28/2019 | Risk Reducing Surgery for Ovarian Cancer. Gynecologic Cancer Symposium. MSKCC. |
| 7/14/2020 | Research Update on Ovarian Cancer. SHARE Webinar Series. |
| 2/09/2021 | Tina's Wish, EmpowHER series: Gynecologic Cancer: Facts and Differences |
| 5/07/2021 | National Ovarian Cancer Wellness Retreat: Updates on Ovarian Cancer |
| 6/9/2024 | Ovarcoming Cancer Annual Conference |

Book Chapters

Corbyn Nchako, **Kara Long**, Ying Liu. Role of Genetics in Gynecologic Malignancies. *Surgical Clinics*. 2026. In preparation.

Sushmita Gordhandas, Emeline Aviki, **Kara Long Roche**. Hereditary Ovarian and Endometrial cancer. *Nezhat's Operative Gynecologic Laparoscopy and Hysteroscopy, 5th Edition*. Cambridge University Press. 2019.

Kara Long Roche, Arlan Fuller, Dennis S. Chi. *Surgical Management of Ovarian Carcinoma*. Fischer's Mastery of Surgery, 7th Edition. Lippincott & Williams. 2017.

Destin Black, **Kara Long Roche**, Ginger Gardner. Fallopian Tube and Peritoneal Cancers, 5th Edition. *Textbook of Uncommon Cancer*. Edited by Derek Raghavan et al. 2017.

Kara C. Long, Dennis S. Chi. Ovarian Cancer: Surgical Considerations. In *Management of Gynecologic Cancers in Older Women*. Springer-Verlag. 2012.

Kara C. Long, Dennis S. Chi. Surgical Management of Ovarian Cancer. In *Clinical Decision Support. Gynecology/Gynecologic Oncology*. Decision Support in Medicine, LLC. 2012.

Kara C. Long, Nadeem R. Abu-Rustum. Clinical Approach to Diagnosis and Management of Cancer of the Cervix and Vulva. In *Surgical Pathology Clinics. Current Concepts in Gynecologic Pathology: Epithelial Tumors of the Gynecologic Tract*. Volume 4, Number 1. W.B. Saunders Company. 2011 Mar;4(1):1-16. (PMID 26837297)

Publications

underlined indicated first or senior authorship

Sowamber R, Mei AJ, Kaur P, McLeod J, McKay E, Lukey A, Bakkum-Gamez J, Buza N, Cohen PA, Devins K, Farrell R, Garcia C, Gilks B, Goode E, Hodgson A, Howitt B, Hui P, Huvila J, Karnezis A, Keyhanian K, Kinloch M, Köbel M, Kommoss FKF, Kushi L, Kwon JS, **Long-Roche K**, Malpica A, McAlpine JN, Miller D, Oliva E, Palicelli A, Paliga A, Parra-Herran C, Pearce CL, Perera S, Piek JM, Qiu H, Rabban J, Rome R, Steenbeek M, Stone R, Talhouk A, Tischer KM, Trabert B, Webb PM, Zalberg JR, Huntsman DG, Hanley GE. Serous Ovarian Cancer Following Opportunistic Bilateral Salpingectomy. *JAMA Netw Open*. 2026 Feb 2;9(2):e2557267. doi: 10.1001/jamanetworkopen.2025.57267. PMID: 41627818.

Ong MM, Mittal L, Lacouture M, Dusza S, Gordon A, Bromberg JF, Goldfarb SB, Iyengar NM, **Long Roche K**, Markova A. No serum estradiol changes with 5-alpha reductase inhibitors for late alopecia in cancer survivors: A retrospective cohort study. *J Am Acad Dermatol*. 2025 Nov 26:S0190-9622(25)03289-X. doi: 10.1016/j.jaad.2025.11.076. Epub ahead of print. PMID: 41314426; PMCID: PMC12765553.

Kahn R, Smith E, Murphy K, Yeoshoua E, Russo L, Zhou Q, Iasonos A, Bennetti G, Ramesh B, Abu-Rustum NR, Chi DS, Zivanovic O, Gardner G, **Long Roche K**, Sonoda Y, Schroeder E, Diaz J, Broach V. Preoperative immunonutrition for patients who undergo primary cytoreductive surgery for ovarian cancer. *Int J Gynecol Cancer*. 2025 Jun 20:101980. doi: 10.1016/j.ijgc.2025.101980. Epub ahead of print. PMID: 40639997.

Chui MH, Kang EY, Kahn RM, Chiang S, Zhou Q, Iasonos A, Manning-Geist B, Selenica P, Da Cruz Paula A, **Long Roche K**, Weigelt B, Grisham RN. Clinicopathologic Features, Molecular Landscape, and Prognostic Implications of Ovarian Low-grade Serous Tumors with Histologic Transformation. *Clin Cancer Res*. 2025 Jul 15;31(14):3084-3095. doi: 10.1158/1078-0432.CCR-24-3168. PMID: 40327333; PMCID: PMC12810708.

Kahn RM, Murphy K, Patel T, Yeoshoua E, Tian E, Finch L, Zhou Q, Iasonos A, Booth P, Honeyman JN, Schefflein J, Crouch M, Kaza S, Broach V, Gardner GJ, **Long Roche K**, Sonoda Y, Abu-Rustum NR, Chi DS. Three-dimensional volumetric rendering on augmented reality headsets for ovarian cancer cytoreduction planning: A Memorial Sloan Kettering Cancer Center Team Ovary study. *Gynecol Oncol*. 2025 Apr 4;196:107-112. Epub ahead of print. PMID: 40187023.

Sullivan MW, Chui MH, Selenica P, **Long Roche K**, Sonoda Y, Grisham RN, Kyi C, Momeni-Boroujeni A, Abu-Rustum NR, Weigelt B, O'Cearbhaill RE. Anaplastic carcinoma of the ovary: A single-institution experience and molecular analysis. *Gynecol Oncol*. 2025 Mar 19;195:144-148. Epub ahead of print. PMID: 40112666.

Dagher C, Lim YH, Sonoda Y, Marshall L, **Long Roche K**, Jewell E, Chi DS, Gardner G, Broach V, Mueller JJ, Abu-Rustum NR, Leitao MM Jr. Oncologic and Perioperative Outcomes of Robot-Assisted Versus Conventional Laparoscopy for the Treatment of Clinically Uterine-Confined High-Grade Adenocarcinoma. *Ann Surg Oncol*. 2024 Dec;31(13):8934-8943. Epub 2024 Sep 24. PMID: 39317893.

Kahn RM, Boerner T, Kim M, Lam C, Gordhandas S, Yeoshoua E, Zhou QC, Iasonos A, Al-Niaimi A, Gardner GJ, **Long Roche K**, Sonoda Y, Zivanovic O, Grisham RN, Abu-Rustum NR, Chi DS. A pre-operative scoring model to estimate the risk of blood transfusion over an ovarian cancer debulking surgery (BLOODS score): a Memorial Sloan Kettering Cancer Center Team Ovary study. *Int J Gynecol Cancer*. 2024 Jul 1;34(7):1051-1059. PMID: 38950927.

Manning-Geist BL, Sullivan MW, Zhou Q, Iasonos A, Selenica P, Stallworth C, Liu YL, **Long Roche K**, Gordhandas S, Aghajanian C, Chi D, O'Cearbhaill R, Grisham RN, Chui MH. Folate receptor alpha expression in low-grade serous ovarian cancer: Exploring new therapeutic possibilities. *Gynecol Oncol*. 2024 Sep;188:52-55. Epub 2024 Jun 27. PMID: 38941962.

Filippova OT, Boecking K, Broach V, Gardner GJ, Sonoda Y, Chi DS, Zivanovic O, **Long Roche K**. Trends in specific procedures performed at the time of cytoreduction for ovarian cancer: Is interval debulking surgery truly less radical? A Memorial Sloan Kettering Cancer Center Team Ovary study. *Gynecol Oncol*. 2024 May 11;187:80-84. Epub ahead of print. PMID: 38735143.

Ehmann S, Lam C, Zhou Q, Iasonos A, Grisham RN, Tew WP, O'Cearbhaill RE, **Long Roche K**, Zivanovic O, Sonoda Y, Chi DS, Gardner GJ. Secondary cytoreductive surgery and oncologic outcomes in the era of targeted maintenance therapy for recurrent, platinum-sensitive ovarian cancer. *Gynecol Oncol*. 2024 Apr 18;186:104-109. Epub ahead of print. PMID: 38640773.

MacArthur E, **Long Roche K**, Sakran J, Patel SH, Najjar P, Lu KH, Gornet M, Frost AS, Walrath M, Bauer T, Oh G, Stone R. Salpingectomy for ovarian cancer prevention: Video education for the surgeon. *Gynecol Oncol Rep*. 2024 Mar 23;53:101368. PMID: 38584804.

Leitao MM Jr, Iasonos A, Tomberlin M, Moukarzel LA, Price H, Bennetti G, Ramesh B, Chi DS, **Long Roche K**, Sonoda Y, Al-Niami A, Mueller JJ, Gardner GJ, Broach V, Jewell EL, Kim S, Feinberg J, Abu-Rustum NR, Zivanovic O. ARIA II: a randomized controlled trial of near-infrared Angiography during Rectosigmoid resection and Anastomosis in women with ovarian cancer. *Int J Gynecol Cancer*. 2024 Mar 21;ijgc-2024-005395. Epub ahead of print. PMID: 38514101.

Byrne M, Sia TY, Fong C, Khurram A, Waters M, Kemel YM, Zhou Q, Ranganathan M, **Long Roche K**, Chi DS, Saban S, Wu M, Varice N, Hamilton JG, Carrot-Zhang J, Abu-Rustum NR, Iasonos A, Ellenson LH, Mandelker D, Weigelt B, Brown CL, Aghajanian C, Stadler Z, Liu YL. Mainstreaming in parallel with ovarian cancer tumor testing to improve genetic testing uptake. *Gynecol Oncol*. 2024 Apr;183:126-132. Epub 2024 Mar 15. PMID: 38493020.

Sia TY, Yaari Z, Feiner R, Smith E, Da Cruz Paula A, Selenica P, Doddi S, Chi DS, Abu-Rustum NR, Levine DA, Weigelt B, Fleisher M, Ramanathan LV, Heller DA, **Long Roche K**. Uterine washings as a novel method for early detection of ovarian cancer: Trials and tribulations. *Gynecol Oncol Rep*. 2024 Feb 3;51:101330. PMID: 38356691.

Kahn RM, Stone RL, **Long Roche KC**. Salpingectomy and Ovarian Cancer Prevention-Reply. *JAMA Surg*. 2024 Apr 1;159(4):470. PMID: 38353988.

Sia TY, Wan V, Finlan M, Zhou QC, Iasonos A, Zivanovic O, Sonoda Y, Chi DS, **Long Roche K**, Jewell E, Tew WP, O'Cearbhaill RE, Cohen S, Makker V, Liu YL, Friedman CF, Kyi C, Zamarin D, Gardner G. Procedural interventions for oligoprogression during treatment with immune checkpoint blockade in gynecologic malignancies: a case series. *Int J Gynecol Cancer*. 2024 Apr 1;34(4):594-601. PMID: 38296517.

Kahn RM, Selenica P, Boerner T, **Roche KL**, Xiao Y, Sia TY, Maio A, Kemel Y, Sheehan M, Salo-Mullen E, Breen KE, Zhou Q, Iasonos A, Grisham RN, O'Cearbhaill RE, Chi DS, Berger MF, Kundra R, Schultz N, Ellenson LH, Stadler ZK, Offit K, Mandelker D, Aghajanian C, Zamarin D, Sabbatini P, Weigelt B, Liu YL. Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival. *Gynecol Oncol*. 2024 Jan;180:35-43. PMID: 38041901.

Kahn RM, Ma X, Gordhandas S, Yeoshoua E, Ellis RJ, Zhang X, Aviki EM, Abu-Rustum NR, Gardner GJ, Sonoda Y, Zivanovic O, Long Roche K, Jewell E, Boerner T, Chi DS. Regionalizing ovarian cancer cytoreduction to high-volume centers and the impact on patient travel in New York State. *Gynecol Oncol*. 2024 Mar;182:141-147. doi: 10.1016/j.ygyno.2024.01.004. Epub 2024 Jan 22. PMID: 38262237; PMCID: PMC10960664.

Boerner T, Lam C, Basaran D, Liu YL, Grisham RN, Tew WP, Long Roche K, Zivanovic O, Abu-Rustum NR, Gardner GJ, Sonoda Y, Chi DS, Soff G, Jewell E. Safety and feasibility of therapeutic anticoagulation for newly diagnosed venous thromboembolism in women who undergo neoadjuvant chemotherapy for

advanced ovarian cancer. *Int J Gynecol Cancer*. 2023 Dec 7;ijgc-2023-004576. doi: 10.1136/ijgc-2023-004576. Epub ahead of print. PMID: 38088180.

Geisler AN, Jain S, Long Roche K, Goldfrank DJ, Markova A, Lacouture ME, Noor SJ. Lichen Sclerosus in Cancer Patients. *J Low Genit Tract Dis*. 2025 Apr 1;29(2):186-189. doi: 10.1097/LGT.0000000000000870. Epub 2025 Feb 6. PMID: 39912802.

Praiss AM, Hirani R, Zhou Q, Iasonos A, Sonoda Y, Abu-Rustum NR, Leitao MM Jr, Long Roche K, Broach V, Gardner GJ, Chi DS, Zivanovic O. Impact of postoperative morbidity on outcomes in patients with advanced epithelial ovarian cancer undergoing intestinal surgery at the time of primary or interval cytoreductive surgery: A Memorial Sloan Kettering Cancer Center Team Ovary study. *Gynecol Oncol*. 2023 Dec;179:169-179. doi: 10.1016/j.ygyno.2023.10.013. Epub 2023 Nov 21. PMID: 37992548.

Kahn RM, Gordhandas S, Godwin K, Stone RL, Worley MJ, Lu KH, **Long Roche K**. Salpingectomy for the primary prevention of ovarian cancer: A review. *JAMA Surgery* 2023 Nov 1;158(11):1204-1211. PMID 37672283.

Stone R, Sakran JV, **Long Roche K**. Salpingectomy in Ovarian Cancer Prevention. *JAMA*. 2023 Jun 20;329(23):2015-2016. PMID: 37261821.

Kahn RM, Stone RL, **Long Roche KC**. Salpingectomy and Ovarian Cancer Prevention-Reply. *JAMA Surg*. 2024 Apr 1;159(4):470. PMID: 38353988.

Sia TY, Maio A, Kemel YM, Arora KS, Gordhandas SB, Kahn RM, Salo-Mullen EE, Sheehan MA, Tejada PR, Bandlamudi C, Zhou Q, Iasonos A, Grisham RN, O'Cearbhaill RE, Tew WP, **Roche KL**, Zivanovic O, Sonoda Y, Gardner GJ, Chi DS, Latham AJ, Carlo MI, Murciano-Goroff YR, Will M, Walsh MF, Robson ME, Mandelker DL, Berger MF, Abu-Rustum NR, Brown CL, Offit K, Hamilton JG, Aghajanian C, Weigelt B, Stadler ZK, Liu YL. Germline Pathogenic Variants and Genetic Counseling by Ancestry in Patients With Epithelial Ovarian Cancer. *JCO Precis Oncol*. 2023 Sep;7. PMID: 37738546

Sia TY, Gordhandas SB, Birsoy O, Kemel Y, Maio A, Salo-Mullen E, Sheehan M, Hensley ML, Rubinstein M, Makker V, Grisham RN, O'Cearbhaill RE, **Roche KL**, Mueller JJ, Leitao MM Jr, Sonoda Y, Chi DS, Abu-Rustum NR, Berger MF, Ellenson LH, Latham A, Stadler Z, Offit K, Aghajanian C, Weigelt B, Mandelker D, Liu YL. Germline drivers of gynecologic carcinosarcomas. *Gynecol Oncol*. 2023 Jul;174:34-41. PMID: 37149903.

Sia TY, Warner AB, Noor SJ, Aviki EM, **Roche KL**. Inflammatory vulvar dermatoses following immune checkpoint inhibitor therapy. *Am J Obstet Gynecol*. 2023 Apr;228(4):469-470. PMID: 36084703.

Ehmann S, Shay K, Zhou Q, Iasonos A, Sonoda Y, Gardner GJ, **Long Roche K**, Zammarrelli WA 3rd, Yeoushoua E, O'Cearbhaill RE, Zivanovic O, Chi DS. Outcomes and long-term follow-up by treatment type for patients with advanced-stage ovarian cancer managed at a tertiary cancer center: A Memorial Sloan Kettering Cancer Center Team Ovary study. *Gynecol Oncol*. 2023 Feb;169:118-124. PMID: 36565685.

Ashley CW, Selenica P, Patel J, Wu M, Nincevic J, Lakhman Y, Zhou Q, Shah RH, Berger MF, Da Cruz Paula A, Brown DN, Marra A, Iasonos A, Momeni-Boroujeni A, Alektiar KM, **Long Roche K**, Zivanovic O, Mueller JJ, Zamarin D, Broach VA, Sonoda Y, Leitao MM, Friedman CF, Jewell E, Reis-Filho JS, Ellenson LH, Aghajanian C, Abu-Rustum NR, Cadoo K, Weigelt B. High-Sensitivity Mutation Analysis of Cell-Free DNA for Disease Monitoring in Endometrial Cancer. *Clin Cancer Res*. 2023 Jan 17;29(2):410-421. PMID: 36007103.

Kahn RM, McMinn E, Yeoushoua E, Boerner T, Zhou Q, Iasonos A, **Long Roche K**, Zivanovic O, Gardner GJ, Sonoda Y, O'Cearbhaill RE, Grisham RN, Tew W, Jones D, Huang J, Park BJ, Abu-Rustum NR, Chi DS. Intrathoracic surgery as part of primary cytoreduction for advanced ovarian cancer: Going to the next

level - A Memorial Sloan Kettering Cancer Center study. *Gynecol Oncol.* 2023 Mar;170:46-53. PMID: 36621269.

Manning-Geist BL, Kahn RM, Nemirovsky D, Girshman J, Laibangyang A, Gordhandas S, Iasonos A, Chui MH, **Long Roche K**, Zivanovic O, Chi DS, Aghajanian C, Grisham RN. Chemotherapy response in low-grade serous ovarian carcinoma at a comprehensive cancer center: Readdressing the roles of platinum and cytotoxic therapies. *Cancer.* 2023 Jul 1;129(13):2004-2012. PMID: 36951509.

Moukarzel LA, Nguyen N, Zhou Q, Iasonos A, Schiavone MB, Ramesh B, Chi DS, Sonoda Y, Abu-Rustum NR, Mueller JJ, **Long Roche K**, Jewell EL, Broach V, Zivanovic O, Leitao MM Jr. Association of bowel preparation with surgical-site infection in gynecologic oncology surgery: Post-hoc analysis of a randomized controlled trial. *Gynecol Oncol.* 2023 Jan;168:100-106. PMID: 36423444.

Manning-Geist BL, Flint M, **Roche KL**. Prevention over screening for ovarian cancer in patients with high-risk germline mutations: Misinterpreting the findings of ALDO. *Gynecol Oncol Rep.* 2023 Mar 2;46:101157. PMID: 36938343.

Feinberg J, Zivanovic O, Hannon M, McCreedy T, Desai P, Kim SH, Aviki EM, Mueller JJ, Jewell EL, **Roche KL**, Gardner GJ, Chi DS, Sonoda Y, Brown CL, Abu-Rustum NR, Cracchiolo JR, Leitao MM Jr, Broach V. Patient-reported symptoms after minimally invasive hysterectomy and association with postoperative complications. *Gynecol Oncol.* 2023 Jun 27;175:163-168. PMID: 37390597.

Liu YL, Manning-Geist BL, Knezevic A, Deng L, Bromberg M, Funt SA, Meisel JL, Zivanovic O, **Roche KL**, Sonoda Y, Gardner GJ, Grisham RN, O'Cearbhaill RE, Tew WP, Abu-Rustum NR, Chi DS, Aghajanian C, Feldman DR. Predicting outcomes in female germ cell tumors using a modified International Germ Cell Cancer Collaborative Group classification system to guide management. *Gynecol Oncol.* 2023 Mar;170:93-101. PMID: 36669327

Lynch KA, Austria MD, Le T, Walters CB, Vickers A, **Roche KL**, Atkinson TM, Carlsson SV. Suggestions for modifications to the Female Sexual Function Index based on cognitive interviews with sexual and gender minority individuals and cisgender, heterosexual persons. *J Sex Med.* 2023 May 26;20(6):871-877. PMID: 37057601.

Praiss AM, Zhou Q, Iasonos A, Moukarzel L, Dessources K, Soldan K, Su K, Sonoda Y, **Roche KL**, Gardner GJ, Troso-Sandoval T, Tew WP, Grisham RN, Chi DS, O'Cearbhaill RE, Zivanovic O. Morbidity after secondary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for ovarian cancer: An analysis of a randomized phase II trial. *Gynecol Oncol.* 2023 Apr;171:23-30. PMID: 36804618.

Vázquez-García I, Uhlitz F, Ceglia N, Lim JLP, Wu M, Mohibullah N, Niyazov J, Ruiz AEB, Boehm KM, Bojilova V, Fong CJ, Funnell T, Grewal D, Havasov E, Leung S, Pasha A, Patel DM, Pourmaleki M, Rusk N, Shi H, Vanguri R, Williams MJ, Zhang AW, Broach V, Chi DS, Da Cruz Paula A, Gardner GJ, Kim SH, Lennon M, **Long Roche K**, Sonoda Y, Zivanovic O, Kundra R, Viale A, Derakhshan FN, Geneslaw L, Issa Bhaloo S, Maroldi A, Nunez R, Pareja F, Stylianou A, Vahdatinia M, Bykov Y, Grisham RN, Liu YL, Lakhman Y, Nikolovski I, Kelly D, Gao J, Schietinger A, Hollmann TJ, Bakhoun SF, Soslow RA, Ellenson LH, Abu-Rustum NR, Aghajanian C, Friedman CF, McPherson A, Weigelt B, Zamarin D, Shah SP. Ovarian cancer mutational processes drive site-specific immune evasion. *Nature.* 2022 Dec;612(7941):778-786. PMID: 36517593.

Kim M, Chen C, Wang P, Mulvey JJ, Yang Y, Wun C, Antman-Passig M, Luo HB, Cho S, **Long-Roche K**, Ramanathan LV, Jagota A, Zheng M, Wang Y, Heller DA. Detection of ovarian cancer via the spectral fingerprinting of quantum-defect-modified carbon nanotubes in serum by machine learning. *Nat Biomed Eng.* 2022 Mar;6(3):267-275. PMID: 35301449.

Z Yaari, Y Yang, E Apfelbaum, C Cupo, A Settle, Q Cullen, W Cai, **K Long Roche**, DA Levine, Fleisher, L Ramanathan, M Zheng, A Jagota, DA Heller. A Perception-Based Machine

Perception Nanosensor Platform to Detect Cancer Biomarkers. *Science Advances*. 2021 Nov 19;7(47). PMID 34797711.

Filippova OT, Selenica P, Pareja F, Vahdatinia M, Zhu Y, Pei X, Riaz N, **Long Roche K**, Chi DS, Abu-Rustum NR, Ellenson LH, Reis-Filho JS, Zamarin D, Weigelt B. Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women. *Gynecol Oncol*. 2021 Mar 2:S0090-8258(21)00173-6. PMID: 33674143.

Valero C, Lee M, Hoen D, Weiss K, Kelly DW, Adusumilli PS, Paik PK, Plitas G, Ladanyi M, Postow MA, Ariyan CE, Shoushtari AN, Balachandran VP, Hakimi AA, Crago AM, **Long Roche KC**, Smith JJ, Ganly I, Wong RJ, Patel SG, Shah JP, Lee NY, Riaz N, Wang J, Zehir A, Berger MF, Chan TA, Seshan VE, Morris LGT. Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. *Nat Commun*. 2021 Feb 1;12(1):729. PMID: 33526794.

Leitao MM Jr, Zhou QC, Schiavone MB, Cowan RA, Smith ES, Iasonos A, Veith M, Rafizadeh M, Curran K, Ramesh B, Chang K, Chi DS, Sonoda Y, Brown AK, Cosin JA, Abu-Rustum NR, Martino MA, Mueller JJ, **Long Roche K**, Jewell EL, Broach V, Lambrou NC, Diaz JP, Zivanovic O. Prophylactic Negative Pressure Wound Therapy After Laparotomy for Gynecologic Surgery: A Randomized Controlled Trial. *Obstet Gynecol*. 2021 Feb 1;137(2):334-341. PMID: 33416292.

Boerner T, Walch HS, Nguyen B, Iasonos A, Zhou QC, Schultz N, Chui MH, Grisham RN, Tew WP, O'Cearbhaill RE, Aghajanian C, Zivanovic O, Abu-Rustum NR, Gardner GJ, Sonoda Y, Chi DS, **Long Roche K**. Exploring the clinical significance of serous tubal intraepithelial carcinoma associated with advanced high-grade serous ovarian cancer: A Memorial Sloan Kettering Team Ovary Study. *Gynecol Oncol*. 2021 Mar;160(3):696-703. PMID: 33386131.

Oseledchyk A, Gemignani ML, Zhou QC, Iasonos A, Elahiji R, Adamou Z, Feit N, Goldfarb SB, **Long Roche K**, Sonoda Y, Goldfrank DJ, Chi DS, Saban SS, Broach V, Abu-Rustum NR, Carter J, Leitao M, Zivanovic O. Surgical ovarian suppression for adjuvant treatment in hormone receptor positive breast cancer in premenopausal patients. *Int J Gynecol Cancer*. 2021 Feb;31(2):222-231. PMID: 33273020.

Straubhar A, Chi DS, **Long Roche K**. Update on the role of surgery in the management of advanced epithelial ovarian cancer. *Clin Adv Hematol Oncol*. 2020 Nov;18(11):723-731. PMID: 33406064.

Valero C, Lee M, Hoen D, Wang J, Nadeem Z, Patel N, Postow MA, Shoushtari AN, Plitas G, Balachandran VP, Smith JJ, Crago AM, **Long Roche KC**, Kelly DW, Samstein RM, Rana S, Ganly I, Wong RJ, Hakimi AA, Berger MF, Zehir A, Solit DB, Ladanyi M, Riaz N, Chan TA, Seshan VE, Morris LGT. The association between tumor mutational burden and prognosis is dependent on treatment context. *Nat Genet*. 2021 Jan;53(1):11-15. PMID: 33398197.

Liu YL, Zhou QC, Iasonos A, Chi DS, Zivanovic O, Sonoda Y, Gardner GJ, Broach VA, O'Cearbhaill RE, Konner JA, Grisham R, Aghajanian CA, Abu-Rustum NR, Tew WP, **Long Roche KC**. Preoperative neoadjuvant chemotherapy cycles and survival in newly diagnosed ovarian cancer: what is the optimal number? A Memorial Sloan Kettering Cancer Center Team Ovary study. *Int J Gynecol Cancer*. 2020 Dec;30(12):1915-1921. PMID 33106271.

Boerner T, **Long Roche K**. Salpingectomy for the Risk Reduction of Ovarian Cancer: Is It Time for a Salpingectomy-alone Approach? *J Minim Invasive Gynecol*. 2020 Oct 8:S1553-4650(20)31082-7. PMID: 33038519.

Straubhar AM, Wolf JL, Zhou MQC, Iasonos A, Cham S, Wright JD, **Long Roche K**, Chi DS, Zivanovic O. Advanced ovarian cancer and cytoreductive surgery: Independent validation of a risk-calculator for perioperative adverse events. *Gynecol Oncol*. 2021 Feb;160(2):438-444. doi: 10.1016/j.ygyno.2020.11.021. Epub 2020 Dec 4. PMID: 33272645; PMCID: PMC7856180.

Straubhar AM, Filippova OT, Cowan RA, Lakhman Y, Sarasohn DM, Nikolovski I, Torrisi JM, Ma W, Abu-Rustum NR, Gardner GJ, Sonoda Y, Zivanovic O, Chi DS, **Long Roche K**. A multimodality triage algorithm to improve cytoreductive outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center team ovary initiative [published online ahead of print, 2020 Jun 6]. *Gynecol Oncol*. 2020;S0090-8258(20)31126-4. PMID 32518012

Boerner T, Filippova OT, Chi AJ, Iasonos A, Zhou QC, **Long Roche K**, Zivanovic O, Park BJ, Huang J, Jones DR, Abu-Rustum NR, Gardner G, Sonoda Y, Chi DS. Video-assisted thoracic surgery in the primary management of advanced ovarian carcinoma with moderate to large pleural effusions: A Memorial Sloan Kettering Cancer Center Team Ovary Study [published online ahead of print, 2020 Aug 10]. *Gynecol Oncol*. 2020;S0090-8258(20)33751-3. PMID: 32792282

Boerner T, Tanner E, Filippova O, Zhou QC, Iasonos A, Tew WP, O'Cearbhaill RE, Grisham RN, Gardner GJ, Sonoda Y, Abu-Rustum NR, Zivanovic O, Long Roche K, Afonso AM, Fischer M, Chi DS. Survival outcomes of acute normovolemic hemodilution in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center Team Ovary study. *Gynecol Oncol*. 2021 Jan;160(1):51-55. PMID: 33213899.

Filippova OT, Kim SW, Cowan RA, Chi AJ, Iasonos A, Zhou QC, Broach V, Zivanovic O, **Long Roche K**, Sonoda Y, Gardner G, Chi DS. Hematologic changes after splenectomy for ovarian cancer debulking surgery, and association with infection and venous thromboembolism. *Int J Gynecol Cancer*. 2020;30(8):1183-1188. PMID 32665236

Long Roche K. Attitudes towards risk-reducing salpingectomy: listen to the patients [published online ahead of print, 2020 Sep 6]. *BJOG*. 2020;10.1111/1471-0528.16465. PMID: 32892497

Pedra Nobre S, Mueller JJ, Gardner GJ, **Long Roche K**, Brown CL, Soslow RA, Alektiar KM, Sonoda Y, Broach VA, Jewell EL, Zivanovic O, Chi DS, Abu-Rustum NR, Leitao MM Jr. Comparison of minimally invasive versus open surgery in the treatment of endometrial carcinosarcoma. *Int J Gynecol Cancer*. 2020;30(8):1162-1168. PMID: 32690592

Pedra Nobre S, Mazina V, Iasonos A, Zhou QC, Sonoda Y, Gardner G, **Long-Roche K**, Leitao MM, Abu-Rustum NR, Mueller JJ. Surveillance patterns of cervical cancer patients treated with conization alone. *Int J Gynecol Cancer*. 2020;30(8):1129-1135. PMID: 32499392

Moukarzel LA, Byrne ME, Leiva S, Wu M, Zhou QC, Iasonos A, Abu-Rustum NR, Sonoda Y, Gardner G, Leitao MM Jr, Broach VA, Chi DS, **Long Roche K**, Zivanovic O. The impact of near-infrared angiography and proctoscopy after rectosigmoid resection and anastomosis performed during surgeries for gynecologic malignancies. *Gynecol Oncol*. 2020;158(2):397-401. PMID: 32460995

Aloisi A, Tseng J, Kuhn T, Feinberg J, Chi DS, Brown CL, Mueller JJ, Gardner GJ, Zivanovic O, Jewell EL, **Long Roche K**, Broach V, Abu-Rustum NR, Leitao MM Jr. Robotic Surgery in the Frail Elderly: Analysis of Perioperative Outcomes. *Ann Surg Oncol*. 2020;27(10):3772-3780. PMID: 32328983

Fung K, Sharma SK, Keinänen O, **Long Roche K**, Lewis J, Zeglis BA. Molecularly Targeted Intraoperative Near-Infrared Fluorescence Imaging Agent for High Grade Serous Ovarian Cancer. Molecular Pharmaceuticals. 2020 Jul 9. PMID 32644804

Long Roche K, Chi DS. Practical guidelines for triage to neoadjuvant chemotherapy in advanced ovarian cancer: Big risk, big reward...or too much risk?. *Gynecol Oncol*. 2020;157(3):561-562. PMID 32527446

Liu YL, Filippova OT, Zhou Q, Iasonos A, Chi DS, Zivanovic O, Sonoda Y, Gardner GJ, Broach VA, O'Cearbhaill RE, Konner JA, Aghajanian C, **Long Roche K***, Tew WP*. Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery. *J Gynecol Oncol*. 2020;31(1):e17. PMID: 31833259

Brandt B, Sioulas V, Basaran D, Kuhn T, LaVigne K, Gardner GJ, Sonoda Y, Chi DS, **Long Roche KC**, Mueller JJ, Jewell EL, Broach VA, Zivanovic O, Abu-Rustum NR, Leitao MM Jr. Minimally invasive surgery versus laparotomy for radical hysterectomy in the management of early-stage cervical cancer: Survival outcomes. *Gynecol Oncol*. 2020;156(3):591-597. PMID: 31918996

Leitao MM Jr, Zhou QC, Gomez-Hidalgo NR, Iasonos A, Baser R, Mezzancello M, Chang K, Ward J, Chi DS, **Long Roche K**, Sonoda Y, Brown CL, Mueller JJ, Gardner GJ, Jewell EL, Broach V, Zivanovic O, Dowdy SC, Mariani A, Abu-Rustum NR. Patient-reported outcomes after surgery for endometrial carcinoma: Prevalence of lower-extremity lymphedema after sentinel lymph node mapping versus lymphadenectomy. *Gynecol Oncol*. 2019 Nov 25. PMID 31780239

Long Roche K, Gardner GJ. State of the Science: Evolving role of surgery for the treatment of ovarian cancer. *Gynecol Oncol*, 2019 Aug 28. PMID 31472939.

Cowan R, Shuk E, Byrne M, Abu-Rustum NR, Chi DS, Boutin-Foster C, Brown CL, **Long Roche K**. Factors associated with utilization of a high-volume cancer center by black women with ovarian cancer. *J Oncology Practice*. 2019. PMID 31335249

Cybulska P, Sioulas V, Orfanelli T, Zivanovic O, Mueller JJ, Broach VA, **Long Roche KC**, Sonoda Y, Hensley ML, O'Cearbhaill RE, Chi DS, Alektiar KM, Abu-Rustum NR, Leitao MM Jr. Secondary surgical resection for patients with recurrent uterine leiomyosarcoma. *Gynecol Oncol*. 2019 Jun 12. PMID 31200927

Stasenکو M, Cybulska P, Feit N, Makker V, Konner J, O'Cearbhaill RE, Alektiar KM, Beal K, Gardner GJ, **Long Roche KC**, Sonoda Y, Chi DS, Zivanovic O, Leitao MM Jr, Cadoo KA, Tew WP. Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation status. *Gynecol Oncol*. 2019 May 18. PMID 31113680

Filippova OT, Chi DS, **Long Roche K**, Sonoda Y, Zivanovic O, Gardner GJ, Tew WP, O'Cearbhaill R, Sarraf S, Sun SW, Alexander K, Korc-Grodzicki B, Shahrokni A. Geriatric co-management leads to safely performed cytoreductive surgery in older women with advanced stage ovarian cancer treated at a tertiary care cancer center. *Gynecol Oncol*. 2019 May 8. PMID 31078241

Haywood S, **Long Roche K**, Bochner B. A thoughtful pause for sparing oophorectomy. *Urology*. 2019. PMID 31005659

Tanner EJ, Filippova OT, Gardner GJ, **Long Roche KC**, Sonoda Y, Zivanovic O, Fischer M, Chi DS. A prospective trial of acute normovolemic hemodilution in patients undergoing primary cytoreductive surgery for advanced ovarian cancer. *Gynecol Oncol*. 2018 Oct 15. PMID 30336947

Tseng JH, Cowan RA, Afonso AM, Zhou Q, Iasonos A, Ali N, Thompson E, Sonoda Y, O'Cearbhaill RE, Chi DS, Abu-Rustum NR, **Long Roche K**. Perioperative epidural use and survival outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer. *Gynecol Oncol*. 2018 Sep 2. PMID 30185381

Tseng JH, Cowan RA, Zhou Q, Iasonos A, Byrne M, Polcino T, Polen-De C, Gardner GJ, Sonoda Y, Zivanovic O, Abu-Rustum NR, **Long Roche K**, Chi DS. Continuous improvement in primary debulking surgery for advanced ovarian cancer: So increased complete gross resection rates independently lead to increased progression-free and overall survival? *Gynecol Oncol*. 2018 Oct;151(1):24-31. PMID 30126704

Cowan RA, Tseng J, Ali N, Dearie H, Murthy V, Gennarelli RL, Iasonos A, Abu-Rustum NR, Chi DS, **Long Roche KC**, Brown CL. Exploring the impact of income and race on survival for women with advanced ovarian cancer undergoing primary debulking surgery at a high-volume center. *Gynecol Oncol*. 2018 Apr;149(1):43-48. PMID: 29605049

Ricci S, Tergas AI, **Long Roche K**, Fairbairn MG, Levinson KL, Dowdy SC, Bristow RE, Lopez M, Slaughter K, Moore K, Fader AN. Geographic disparities in the distribution of the U.S. gynecologic oncology workforce: a Society of Gynecologic Oncology study. *Gynecol Oncol Rep*. 2017 Nov 15;22:100-104. PMID: 29201989

Oseledchik A, Leitao MM Jr, Konner J, O'Cearbhaill RE, Zamarin D, Sonoda Y, Gardner GJ, **Long Roche K**, Aghajanian CA, Grisham RN, Brown CL, Snyder A, Chi DS, Soslow RA, Abu-Rustum NR, Zivanovic O. Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era: a Surveillance, Epidemiology, and End Results Cohort Study, 2000-2013. *Ann Oncol*. 2017 Dec 1;28(12):2985-2993. PMID: 28950307

Cowan RA, Tseng J, Murthy V, Srivastava R, **Long Roche KC**, Zivanovic O, Gardner GJ, Chi DS, Park BJ, Sonoda Y. Feasibility, safety, and clinical outcomes of cardiophrenic lymph node resection in advanced ovarian cancer. *Gynecol Oncol*. 2017 Nov;147(2):262-266. PMID: 28888540

Lippitt MH, Fairbairn MG, Matsuno R, Stone RL, Tanner EJ 3rd, Wick EC, Angarita AC, **Roche KL**, Levinson KL, Bergstrom JE, Sinno AK, Curless MS, Wethington S, Temkin SM, Efron J, Hobson D, Fader AN. Outcomes associated with a five-point surgical site infection prevention bundle in women undergoing surgery for ovarian cancer. *Obstet Gynecol*. 2017 Oct;130(4):756-764. PMID: 28885412

Fader AN, Bergstrom J, Jernigan A, Tanner EJ 3rd, **Roche KL**, Stone RL, Levinson KL, Ricci S, Wethington S, Wang TL, Shih IM, Yang B, Zhang G, Armstrong DK, Gaillard S, Michener C, DeBernardo R, Rose PG. Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival? *Gynecol Oncol*. 2017 Oct;147(1):85-91. PMID: 28768570

Schiavone MB, Moukarzel L, Leong K, Zhou QC, Afonso AM, Iasonos A, **Roche KL**, Leitao MM Jr, Chi DS, Abu-Rustum NR, Zivanovic O. Surgical site infection reduction bundle in patients with gynecologic cancer undergoing colon surgery. *Gynecol Oncol*. 2017 Oct;147(1):115-119. PMID: 28734498

Eriksson AG, Beavis A, Soslow RA, Zhou Q, Abu-Rustum NR, Gardner GJ, Zivanovic O, **Long Roche K**, Sonoda Y, Leitao MM Jr, Jewell EL. A comparison of the detection of sentinel lymph nodes using Indocyanine Green and near infrared fluorescence imaging versus blue dye during robotic surgery in uterine cancer. *Int J Gynecol Cancer*. 2017 May;27(4):743-747. PMID: 28375931

Sinno A, Li X, Thompson RE, Tanner EJ 3rd, Levinson KL, Stone RL, Temkin SM, Fader AN, Chi DS, **Long Roche K**. Trends and factors associated with radical cytoreductive surgery in the United States: A case for centralized care. *Gynecol Oncol* 2017 Mar 30. PMID 28366546

Long Roche KC, Abu-Rustum NR, Nourmoussavi M, Zivanovic O. Risk-reducing salpingectomy: Let us be opportunistic. *Cancer*. 2017 Mar 23 PMID: 28334425

Sioulas VD, Schiavone MB, Kadouri D, Zivanovic O, **Roche KL**, O'Cearbhaill R, Abu-Rustum NR, Levine DA, Sonoda Y, Gardner GJ, Leitao MM Jr, Chi DS. Optimal primary management of bulky stage IIIc ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy? *Gynecol Oncol*. 2017 Feb 18. PMID 28238354

Suidan RS, Ramirez PT, Sarasohn DM, Teitcher JB, Iyer RB, Zhou Q, Iasonos A, Denesopolis J, Zivanovic O, **Long Roche KC**, Sonoda Y, Coleman RL, Abu-Rustum NR, Hricak H, Chi DS. A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer. *Gynecol Oncol*. 2017 Feb 13. PMID: 28209497

Mueller JJ, Kelly A, Zhou Q, Iasonos A, **Long Roche K**, Sonoda Y, O'Cearbhaill RE, Zivanovic O, Chi DS, Gardner GJ. Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage

ovarian cancer: Feasibility and outcomes at a comprehensive cancer center. *Gynecol Oncol.* 2016 Dec;143(3):496-503. PMID: 27692668

Long Roche K, Angarita AM, Cristello A, Lippitt M, Haider AH, Bowie JV, Fader AN, Tergas AI. "Little Big Things": A Qualitative Study of Ovarian Cancer Survivors and Their Experiences With the Health Care System. *J Oncol Pract.* 2016 Dec;12(12):e974-e980. PMID: 27601509

Desale MG, Tanner EJ 3rd, Sinno AK, Angarita AA, Fader AN, Stone RL, Levinson KL, Bristow RE, **Roche KL**. Perioperative fluid status and surgical outcomes in patients undergoing cytoreductive surgery for advanced epithelial ovarian cancer. *Gynecol Oncol.* 2016 Oct 28. PMID: 28029449

Tseng JH, Suidan RS, Zivanovic O, Gardner GJ, Sonoda Y, Levine DA, Abu-Rustum NR, Tew WP, Chi DS, **Long Roche K**. Diverting ileostomy during primary debulking surgery for ovarian cancer: Associated factors and postoperative outcomes. *Gynecol Oncol.* 2016 Aug;142(2):217-24. PMID: 27261325

Schlappe BA, Mueller JJ, Zivanovic O, Gardner GJ, **Long Roche K**, Sonoda Y, Chi DS, O'Cearbhaill RE. Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center. *Gynecol Oncol.* 2016 Jul;142(1):13-8. PMID: 27189456

Wu ES, Oduyebo T, Cobb LP, Cholakian D, Kong X, Fader AN, Levinson KL, Tanner EJ 3rd, Stone RL, Piotrowski A, Grossman S, **Long Roche K**. Lymphopenia and its association with survival in patients with locally advanced cervical cancer. *Gynecol Oncol.* 2016 Jan;140(1):76-82. PMID 26571200

Cowan RA, O'Cearbhaill RE, Gardner GJ, Levine DA, **Roche KL**, Sonoda Y, Zivanovic O, Tew WP, Sala E, Lakhman Y, Vargas Alvarez HA, Sarasohn DM, Mironov S, Abu-Rustum NR, Chi DS. Is It Time to Centralize Ovarian Cancer Care in the United States? *Ann Surg Oncol.* 2016 Mar;23(3):989-93. PMID 26511267

Tanner EJ, Sinno AK, Stone RL, Levinson KL, **Long KC**, Fader AN. Factors associated with successful bilateral sentinel lymph node mapping in endometrial cancer. *Gynecol Oncol.* 2015 Sep;138(3):542-7. PMID 26095896

Suidan RS, Leitao MM Jr, Zivanovic O, Gardner GJ, **Long Roche KC**, Sonoda Y, Levine DA, Jewell EL, Brown CL, Abu-Rustum NR, Charlson ME, Chi DS. Predictive value of the Age-Adjusted Charlson Comorbidity Index on perioperative complications and survival in patients undergoing primary debulking surgery for advanced epithelial ovarian cancer. *Gynecol Oncol.* 2015 Aug;138(2):246-51. PMID 26037900

Tseng JH, **Roche KL**, Jernigan AM, Salani R, Bristow RE, Fader AN. Lifestyle and Weight Management Counseling in Uterine Cancer Survivors: A Study of the Uterine Cancer Action Network. *Int J Gynecol Cancer.* 2015 Sep;25 (7):1285-91. PMID: 25966932

Mantha S, Sarasohn D, Ma W, Devlin SM, Chi DS, **Roche KL**, Suidan RS, Woo K, Soff GA. Ovarian Vein Thrombosis After Debulking Surgery for Ovarian Cancer: Epidemiology and Clinical Significance. *American Journal of Obstetrics and Gynecology.* *Am J Obstet Gynecol.* 2015 Aug;213(2):208. PMID 25743130

Kushnir CL, Angarita AM, Havrilesky LJ, Thompson S, Spahlinger D, Sinno AK, Tanner EJ, Secord AA, **Roche KL**, Stone RL, Fader AN. Selective cardiac surveillance in patients with gynecologic cancer undergoing treatment with pegylated liposomal doxorubicin (PLD). *Gynecol Oncol.* 2015 Jun;137(3):503-7. PMID 25735254

Suidan RS, Zhou Q, Iasonos A, O'Cearbhaill RE, Chi DS, **Long Roche KC**, Tanner EJ, Denesopolis J, Barakat RR, Zivanovic O. Prognostic significance of the number of postoperative intraperitoneal chemotherapy cycles for patients with advanced epithelial ovarian cancer. *Int J Gynecol Cancer.* 2015 May;25(4):599-606. PMID 25664437

Ramos A, Nickles Fader A, **Long Roche K**. Surgical Cytorreduction for Disseminated Benign Disease After Open Power Uterine Morcellation. *Obstet Gynecol*. 2015. Jan;125(1):99-102. PMID 25560110

Suidan RS, St. Clair CM, Lee SJ, Barlin JN, **Long Roche KC**, Tanner EJ, Sonoda Y, Richard R. Barakat RR, Zivanovic O, Chi DS. A Comparison of Primary Intraperitoneal Chemotherapy to Consolidation Intraperitoneal Chemotherapy in Optimally Resected Advanced Ovarian Cancer. *Gynecol Oncol*. 2014.Sep;134(3):468-72. PMID: 25042672

Sinno AK, Fader AN, **Roche KL**, Giuntoli II RL, Tanner EJ. A Comparison of Colorimetric versus Fluorometric Sentinel Lymph Node Mapping During Robotic Surgery for Endometrial Cancer. *Gynecol Oncol*. Aug;134(2):281-6. PMID: 24882555

Sandadi S, **Long K**, Andikyan V, Vernon J, Zivanovic O, Eisenhauer EL, Levine DA, Sonoda Y, Barakat RR, Chi DS. Postoperative outcomes among patients undergoing thoracostomy tube placement at time of diaphragm peritonectomy or resection during primary cytoreductive surgery for ovarian cancer. *Gynecol Oncol*. 2014 Feb;132(2):299-302. PMID: 24296344

Tanner EJ, **Long KC**, Visvanathan K, Fader AN. Prophylactic salpingectomy in premenopausal women at low risk for ovarian cancer: risk-reducing or risky? *Fertil Steril*. 2013 Dec; 100(6):1530-1. PMID: 24182408

Long KC, Tanner EJ, Frey M, Leitao MM Jr, Levine DA, Gardner GJ, Sonoda Y, Abu-Rustum NR, Barakat RR, Chi DS. Intraoperative hypothermia during primary surgical cytorreduction for advanced ovarian cancer: Risk factors and associations with postoperative morbidity. *Gynecol Oncol*. 2013. Sept 7. PMID: 24016410

Long KC, Kauff ND. Screening for Familial Ovarian Cancer: A Ray of Hope and a Light to Steer by. Editorial. *J Clin Oncol*. 2012. Dec 3. Vol 30. PMID: 23213103.

Tanner EJ, **Long KC**, Feffer JB, Leitao, Jr MM, Abu-Rustum NR, Barakat RR, Chi DS. Parenchymal Splenic Metastasis is an Independent Negative Predictor of Overall Survival in Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer. *Gynecol Oncol*. 2012 Sept 25. PMID: 23017819

Hyman DM, **Long KC**, Tanner EJ, Grisham RN, Arnold AG, Bhatia J, Spriggs DR, Soslow RA, Kauff ND, Levine DA. Outcomes of Primary Surgical Cytorreduction in Patients with *BRCA*-associated High-grade Serous Ovarian Carcinoma. *Gynecol Oncol*. 2012 Aug; 126(2):224-8. PMID: 22579790

Tanner EJ, **Long KC**, Zhou Q, Brightwell R, Gardner GJ, Abu-Rustum NR, Leitao, Jr. MM, Sonoda Y, Barakat RR, Iasonos A, Chi DS. Impact of Operative Start Time on Surgical Outcomes in Patients Undergoing Primary Cytorreduction for Advanced Ovarian Cancer. *Gynecol Oncol*. 2012 Jul; 126(1):58-63. PMID: 22507533

Long KC, Zhou Q, Hensley ML, Alektiar KM, Gomez J, Gardner GJ, Chi DS, Barakat RR, Abu-Rustum NR. Patterns of recurrence in 1988 FIGO stage IC endometrioid endometrial cancer. *Gynecol Oncol*. 2012 Apr; 125(1):99-102. PMID: 22112609

Long KC, Kauff ND. Hereditary ovarian cancer: recent molecular insights and their impact on screening strategies. *Curr Opin Oncol*. 2011 Sep; 23(5):526-30. PMID: 21734577

Noyes N, Knopman JM, **Long KC**, Coletta JM, Abu-Rustum NR. Fertility Considerations in the Management of Gynecologic Malignancies. *Gynecol Oncol*. 2011 Mar; 120(3):326-333. PMID: 20943258

Long KC, Levinson KL, Diaz JP, Gardner GJ, Chi DS, Barakat RR, Leitao Jr. MM. Ventral hernia following primary laparotomy for ovarian, fallopian tube, and primary peritoneal cancer. *Gynecol Oncol*. 2011 Jan; 120(1):33-37. PMID: 20947151

Hope JM, **Long K**, Kudla M, Arslan A, Tsymbal T, Strok I, Timor-Tritsch I. Three- dimensional power doppler angiography of cyclic ovarian blood flow. J Ultrasound Med. 2009 Aug; 28(8):1043-52. PMID: 19643787

Hope JM, Wang F, Whyte JS, Ariztia E, Abdalla W, **Long K**, Fishman DA. LPA receptor 2 mediates LPA-induced endometrial cancer invasion. Gynecol Oncol. 2009 Jan; 112(1):215-23. PMID: 19019417